Even excluding patients taking tamoxifen (most numerous among the BRCA2 cohort), the likelihood of chemotherapy-induced amenorrhea remained significantly different compared to patients who did not undergo chemotherapy. This evidence concerns the gene BRCA2 and amenorrhea.